STOCKHOLM, SWEDEN / RankWire.AI / – Karl Deisseroth, Peter Hegemann and Georg Nagel received the 2026 Nobel Prize in Physiology or Medicine for pioneering discoveries that laid the foundation for optogenetics. The Nobel Assembly at Karolinska Institutet announced the honor on October 5. Their research provided scientists with an exact method to manipulate specific nerve cells with light. Today, this technique is integral to investigations of brain circuits, behavior, memory, and illness, becoming one of neuroscience’s most vital experimental tools.
Hegemann and Nagel elucidated the function of channelrhodopsin in the green alga Chlamydomonas. This protein creates a light-sensitive channel in the cell membrane, which blue light opens, allowing charged ions to pass through and generate electrical activity inside the cell. Their experiments demonstrated that channelrhodopsin could be inserted into other cells to respond to light. This discovery laid the groundwork for controlling cell activity via light flashes.
Deisseroth later adapted this finding for neuroscience. In 2005, he proved that channelrhodopsin could induce rat nerve cells to respond to blue light, showing that electrical signals could be triggered selectively. Subsequent research confirmed the method’s effectiveness in living animals. These advances turned optogenetics into a practical tool for examining how specific brain circuits influence activity and behavior, offering much greater precision than previous techniques.
Optogenetics revolutionizes brain research with light-based control
Combining genetic targeting with light-sensitive proteins, researchers can activate or silence particular groups of nerve cells. This control enables scientists to investigate how distinct circuits contribute to movement, learning, emotion, and memory. The Nobel Committee stated that the technique transformed in vivo brain research, providing a way to link activity in specific cells with observable behavioral changes. It allows targeted cell studies without simultaneously stimulating broader tissue areas.
Today, optogenetics is employed in research on Parkinson’s disease, epilepsy, depression, addiction, and other disorders. Investigators are also exploring related methods for severe vision loss, aiming to restore light responsiveness in retinal cells. These medical applications are still experimental and not yet standard treatments. Currently, its primary role remains in research, where it offers high-precision analysis of complex biological systems, extending beyond neuroscience into other cell biology fields.
Three scientists share the Nobel prize for medicine
Deisseroth is affiliated with Stanford University and works as an investigator at the Howard Hughes Medical Institute in the US. Hegemann is based at Humboldt University of Berlin, while Nagel is with the University of Würzburg in Germany. The trio will divide a prize of 12 million Swedish kronor. Their individual yet interconnected contributions trace the development of modern optogenetics—from discovering light-sensitive proteins to characterizing and utilizing them to control nerve cells.
This award highlights a scientific journey that began with a simple organism and revolutionized brain research. Channelrhodopsin provided the molecular switch enabling precise light control. Deisseroth’s work brought this switch into nerve cells and living brains. Today, optogenetics is widely used across neuroscience and biology. The laureates will be honored with Nobel medals and diplomas in Stockholm on December 10, in accordance with Nobel tradition, coinciding with the anniversary of Alfred Nobel’s death.